Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

Study acronym: STOP KNEE-OA
StatusActive, Not Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Eligibility criteria expanded, about 40 words
    • Secondary endpoints: details revised at 6 of 16 entries
    • Site details revised at 4 of 4 sites
    • Publications: details revised at 1 of 1 entry
  2. Site contacts updated at 4 of 4 sitesv6
  3. Study sites: 1 to 4
    • Eligibility criteria expanded, about 48 words
    • Secondary endpoints: details revised at 2 of 16 entries
    v5
  4. Start date changed from estimate of Oct 2024 to Nov 19, 2024v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: May 2024 to Oct 2024
    • Study site revised
    v3
  6. Secondary endpoints: details revised at 6 of 16 entriesv2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main purpose of this study is to see if tirzepatide can reduce number of these participants who require a knee replacement. Participants will be randomized to take a weekly injection of tirzepatide or a placebo for a total of 72 weeks.
Trial Details
NCT Number NCT06191848
Lead Sponsor University of Melbourne
Collaborators: Eli Lilly and Company
Conditions
(from sponsor)		 Obesity, Knee Osteoarthritis, Osteoarthritis, Knee
Related terms Obesity, Osteoarthritis, Osteoarthritis, Knee
Enrollment 352 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov